Back to all studies
🧬
Phase 3
Neurology
in-person

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Sponsored by Bristol-Myers Squibb

Compensation

Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.

Duration

3 months

Location

Nationwide

About this study

The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.

Who can participate

  • • Adults aged 55–90
  • • All genders welcome
  • • Diagnosed with or experiencing alzheimer disease
  • • Able to attend in-person clinic visits

What's included

  • • Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.
  • • All study-related medical care at no cost
  • • Lab work, screenings, and physician consultations
  • • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.

Source: ClinicalTrials.gov record NCT06937229

Ready to Find a Research Study?

Explore clinical trials and paid research opportunities. Compensation varies by study and is never guaranteed.